Pleiotropic effects of statin therapy: molecular mechanisms and clinical results

Chao Yung Wang, Ping Yen Liu, James K. Liao

Research output: Contribution to journalReview articlepeer-review

432 Citations (Scopus)

Abstract

Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels. However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such as Rho, Rac and Cdc42. Therefore, it is possible that statins might exert cholesterol-independent or 'pleiotropic' effects through direct inhibition of these small GTP-binding proteins. Recent studies have shown that statins might have important roles in diseases that are not mediated by cholesterol. Here, we review data from recent clinical trials that support the concept of statin pleiotropy and provide a rationale for their clinical importance.

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalTrends in Molecular Medicine
Volume14
Issue number1
DOIs
Publication statusPublished - 2008 Jan

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Pleiotropic effects of statin therapy: molecular mechanisms and clinical results'. Together they form a unique fingerprint.

Cite this